318 related articles for article (PubMed ID: 10825478)
1. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Zhou W; Hurlbert MS; Schaack J; Prasad KN; Freed CR
Brain Res; 2000 Jun; 866(1-2):33-43. PubMed ID: 10825478
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
Zhou W; Schaack J; Zawada WM; Freed CR
Brain Res; 2002 Feb; 926(1-2):42-50. PubMed ID: 11814405
[TBL] [Abstract][Full Text] [Related]
3. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line.
Lotharius J; Barg S; Wiekop P; Lundberg C; Raymon HK; Brundin P
J Biol Chem; 2002 Oct; 277(41):38884-94. PubMed ID: 12145295
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
[TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of Parkinson's disease-associated alpha-synucleinA53T by recombinant adeno-associated virus in mice does not increase the vulnerability of dopaminergic neurons to MPTP.
Dong Z; Ferger B; Feldon J; Büeler H
J Neurobiol; 2002 Oct; 53(1):1-10. PubMed ID: 12360578
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
8. Regulation of alpha-synuclein by bFGF in cultured ventral midbrain dopaminergic neurons.
Rideout HJ; Dietrich P; Savalle M; Dauer WT; Stefanis L
J Neurochem; 2003 Feb; 84(4):803-13. PubMed ID: 12562524
[TBL] [Abstract][Full Text] [Related]
9. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
10. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
11. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotective effects of erythropoietin on 6-hydroxydopamine-treated ventral mesencephalic dopamine-rich cultures.
Ganser C; Papazoglou A; Just L; Nikkhah G
Exp Cell Res; 2010 Mar; 316(5):737-46. PubMed ID: 20060824
[TBL] [Abstract][Full Text] [Related]
13. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine.
Junn E; Mouradian MM
Neurosci Lett; 2002 Mar; 320(3):146-50. PubMed ID: 11852183
[TBL] [Abstract][Full Text] [Related]
14. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
Wersinger C; Prou D; Vernier P; Sidhu A
FASEB J; 2003 Nov; 17(14):2151-3. PubMed ID: 12958153
[TBL] [Abstract][Full Text] [Related]
15. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
16. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
17. A Drosophila model of Parkinson's disease.
Feany MB; Bender WW
Nature; 2000 Mar; 404(6776):394-8. PubMed ID: 10746727
[TBL] [Abstract][Full Text] [Related]
18. Fate of midbrain dopaminergic neurons controlled by the engrailed genes.
Simon HH; Saueressig H; Wurst W; Goulding MD; O'Leary DD
J Neurosci; 2001 May; 21(9):3126-34. PubMed ID: 11312297
[TBL] [Abstract][Full Text] [Related]
19. Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG; Hastings TG
J Neurochem; 2004 Jun; 89(6):1318-24. PubMed ID: 15189334
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity.
Zhou W; Freed CR
J Biol Chem; 2004 Mar; 279(11):10128-35. PubMed ID: 14699135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]